Press releases worldwide
. Lonza will invest approximately CHF 850 million to build two new state-of-the-art mammalian facilities and respond to customer demand regarding capacity, life cycle management and speed to market A new large-scale facility with the latest manufacturing technology in Visp […]
Lonza will invest CHF 200 million to construct a new manufacturing complex The 2000 m2 complex will include a customer dedicated manufacturing line for antibody-drug conjugate payload molecules The investment is supported by a long-term collaboration and capital contribution with […]
Finalisation de la vente des sites Lonza de Ploermel (FR) et d’Edimbourg (UK) Un processus de transfert de propriété sans heurts reste une priorité Citation de Gordon Bates, président et responsable de la division Small Molecules, Lonza : "La cession […]
Completion of sale of Lonza sites in Ploermel (FR) and Edinburgh (UK) A seamless ownership transfer process remains a priority Quote from Gordon Bates, President and Head of Small Molecules, Lonza: “The strategic divestment of our Ploermel and Edinburgh sites […]
Lonza Specialty Ingredients to be sold to Bain Capital and Cinven for an enterprise value of CHF 4.2 billion Divestment will allow Lonza to refocus its business as a pure-play partner to the healthcare industry Successful track record of investment […]
. Agreement initiates process for future acquisition of Lonza sites in Ploermel (FR) and Edinburgh (UK) allowing NextPharma to broaden technology offering into lipid finished dosage forms Centers of excellence employing a total of 390 staff offer expertise in Lipid […]
Two new bioconjugation suites to provide high throughput conjugation for the commercialization of antibody-drug conjugates (ADCs) in Lonza’s Ibex®Dedicate 1500m2 of active manufacturing space in addition to established quality control (QC) labs, logistics and other central services Long-term collaboration with […]
. Quote from Pierre-Alain Ruffieux, Chief Executive Officer, Lonza: “We congratulate Moderna on this important milestone, which represents a significant scientific achievement and serves as a testament to Moderna’s commitment to controlling the COVID-19 pandemic. “We are proud […]
Pierre-Alain Ruffieux today commences his role as Chief Executive Officer, following his appointment in June 2020. Albert M. Baehny resumes his role as Chairman of the Board of Directors, after a year in the role of Chief Executive Officer ad […]
Lonza provides the details of its new structural design, culture and external reporting 2023 Group guidance: double-digit sales growth, CORE EBITDA margin of around 33% – 35% and double-digit ROIC CAPEX in 2021 and 2022 is likely to remain at […]